Innovactiv says its signature ingredient has two health claims for blood sugar control.
Health Canada has granted two health claims for InSea2 and blood sugar management, says the ingredient’s developer, InnoVactiv (Rimouski, QC, Canada).
InSea2 is a proprietary blend of extracts from brown seaweed (Ascophyllum nodosum) and bladderwrack (Fucus vesiculosus). Under Natural Product Number (NPN) #80033840, qualified products formulated with the InSea2 seaweed extract can run either of the following claims:
Innovactiv says its ingredient can slow the digestion of starch and table sugar, which reduces blood sugar spikes and helps control insulin levels after consuming a meal. The ingredient is backed by clinical studies demonstrating these effects.
“As a critical component of metabolic syndrome, maintaining healthy blood sugar should be at the core of any health-promoting strategy,” says InnoVactiv CEO Patrice Dionne. “Formulating dietary supplements with InSea2 offers a convenient and effective option for those seeking help with their blood sugar level.”
Both Canadian health claims are available for products using InSea2 within a range of 250 to 1000 mg. The company says InSea2 easily incorporates into capsules, tablets, drinks, and functional foods.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.